Taken together, these results strongly suggest that RELA and STAT5 co-regulated Bcl-X promoter in response to carboplatin, and conferred chemoresistance in ovarian cancer, in part, through the transcriptional activation of Bcl-xL. This evidence concerns the gene BCL2L1 and ovarian carcinoma.